Literature DB >> 27289477

Antidepressant use and risk of central nervous system metastasis.

Megan M Herr1, Nimish A Mohile2, Edwin van Wijngaarden3, Edward B Brown4, David Q Rich3.   

Abstract

Selective serotonin reuptake inhibitors (SSRIs), a class of antidepressants, were found to increase central nervous system (CNS) metastasis in mice. Our study investigated in humans whether antidepressants, and specifically SSRIs, increased the relative odds of CNS metastasis. We identified 189 cases of CNS metastasis amongst breast cancer, melanoma, and non-Hodgkin lymphoma subjects who were diagnosed with CNS metastasis or infiltration between January 1, 2005 and September 30, 2013 and 756 controls (patients without CNS metastasis or infiltration). Using logistic regression, we estimated the relative odds of CNS metastasis associated with antidepressant use adjusting for relevant covariates. The prevalence of antidepressants was 28.6 % in cases and 27.5 % in controls, whereas SSRIs were used in 16.9 % of cases and 17.3 % of controls. Among all patients, antidepressants were not associated with CNS metastasis or infiltration. No consistent patterns of association were observed in the analyses of other cancer subsets or exposure measures, with the possible exception of an increased risk of CNS metastasis associated with 'any SSRI use' among breast cancer patients (OR = 1.73, 95 % CI = 0.75, 4.04). We did not observe clear patterns of association, which may be due in part to the small sample size in many of our analyses.

Entities:  

Keywords:  Antidepressant; Brain metastasis; Breast Cancer; Central nervous system (CNS) metastasis; Melanoma; Selective serotonin reuptake inhibitor (SSRI)

Mesh:

Substances:

Year:  2016        PMID: 27289477     DOI: 10.1007/s11060-016-2165-2

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  50 in total

Review 1.  Leukocyte transendothelial migration: orchestrating the underlying molecular machinery.

Authors:  R A Worthylake; K Burridge
Journal:  Curr Opin Cell Biol       Date:  2001-10       Impact factor: 8.382

2.  Changes in the prevalence of psychological distress and use of antidepressants or anti-anxiety medications associated with comorbid chronic diseases in the adult Australian population, 2001-2008.

Authors:  Evan Atlantis; Thomas Sullivan; Norman Sartorius; Osvaldo P Almeida
Journal:  Aust N Z J Psychiatry       Date:  2012-01-05       Impact factor: 5.744

3.  Central nervous system relapse in non-Hodgkin lymphoma. A single-center study of 532 patients.

Authors:  E L Bollen; R E Brouwer; S Hamers; J Hermans; M Kluin; S U Sankatsing; R V A-Tjak; M V Charvat; J C Kluin-Nelemans
Journal:  Arch Neurol       Date:  1997-07

4.  Unfavourable pattern of metastases in M0 breast cancer patients during 1978-2008: a population-based analysis of the Munich Cancer Registry.

Authors:  Corina J G van den Hurk; Renate Eckel; Lonneke V van de Poll-Franse; Jan Willem W Coebergh; Johan W R Nortier; Dieter Hölzel; Wim P M Breed; Jutta Engel
Journal:  Breast Cancer Res Treat       Date:  2011-02-11       Impact factor: 4.872

5.  Fatigue in breast cancer survivors two to five years post diagnosis: a HEAL Study report.

Authors:  Kathleen Meeske; Ashley Wilder Smith; Catherine M Alfano; Bonnie A McGregor; Anne McTiernan; Kathy B Baumgartner; Kathleen E Malone; Bryce B Reeve; Rachel Ballard-Barbash; Leslie Bernstein
Journal:  Qual Life Res       Date:  2007-04-25       Impact factor: 4.147

6.  Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype.

Authors:  Nils D Arvold; Kevin S Oh; Andrzej Niemierko; Alphonse G Taghian; Nancy U Lin; Rita F Abi-Raad; Meera Sreedhara; Jay R Harris; Brian M Alexander
Journal:  Breast Cancer Res Treat       Date:  2012-09-12       Impact factor: 4.872

7.  Distribution of brain metastases.

Authors:  J Y Delattre; G Krol; H T Thaler; J B Posner
Journal:  Arch Neurol       Date:  1988-07

8.  Distress, psychiatric morbidity, and prescriptions for psychotropic medication in a breast cancer waiting room sample.

Authors:  James C Coyne; Steven C Palmer; Pamela J Shapiro; Richard Thompson; Angela DeMichele
Journal:  Gen Hosp Psychiatry       Date:  2004 Mar-Apr       Impact factor: 3.238

9.  Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study.

Authors:  Harri Sihto; Johan Lundin; Mikael Lundin; Tiina Lehtimäki; Ari Ristimäki; Kaija Holli; Liisa Sailas; Vesa Kataja; Taina Turpeenniemi-Hujanen; Jorma Isola; Päivi Heikkilä; Heikki Joensuu
Journal:  Breast Cancer Res       Date:  2011-09-13       Impact factor: 6.466

10.  Anti-inflammatory properties of desipramine and fluoxetine.

Authors:  Caroline Roumestan; Alain Michel; Florence Bichon; Karine Portet; Maëlle Detoc; Corinne Henriquet; Dany Jaffuel; Marc Mathieu
Journal:  Respir Res       Date:  2007-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.